Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Activities of Daily Living
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Breast Neoplasms
/ complications
Female
Follow-Up Studies
Furans
/ administration & dosage
Geriatric Assessment
/ statistics & numerical data
Humans
Italy
Ketones
/ administration & dosage
Neoplasm Recurrence, Local
/ complications
Prospective Studies
Quality of Life
Treatment Outcome
Tubulin Modulators
/ administration & dosage
Comprehensive geriatric assessment
Elderly
Eribulin mesylate
Health‐related quality of life
Metastatic breast cancer
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
22
12
2017
accepted:
28
08
2018
pubmed:
11
11
2018
medline:
21
7
2020
entrez:
11
11
2018
Statut:
ppublish
Résumé
Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group for Geriatric Oncology) was designed to assess the efficacy and tolerability of eribulin, according to parameters usually used in geriatric oncology. An observational study was conducted on 50 consecutive elderly patients with MBC. The primary endpoint was to evaluate the change in items score of comprehensive geriatric assessment (CGA) and health-related quality of life (HRQL). Italian versions of the CGA and HRQL questionnaires were administered at baseline, before the third and fifth cycles, and then every three cycles until treatment discontinuation. Secondary endpoints were efficacy and safety. Overall, both EQ-5D scores and EQ-5D-3 L visual analogic scale did not significantly change from baseline; the percentage of subjects without problems doing usual activities tended to decrease during treatment ( Eribulin treatment preserved quality of life and geriatric parameters included in the CGA, except for instrumental functioning and geriatric depression, in elderly patients with MBC. A collaboration between oncologist and geriatric specialists is essential in the management of patients with metastatic breast cancer, who are frequently elderly or frail. The assessment of geriatric parameters in the decision-making process can contribute to direct toward the most appropriate therapeutic plan and preserve the quality of life of patients. Eribulin does not seem to affect quality of life or worsen the overall geriatric status; therefore, it can be considered a suitable option for elderly patients with metastatic breast cancer.
Sections du résumé
BACKGROUND
Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group for Geriatric Oncology) was designed to assess the efficacy and tolerability of eribulin, according to parameters usually used in geriatric oncology.
SUBJECTS, MATERIALS, AND METHODS
An observational study was conducted on 50 consecutive elderly patients with MBC. The primary endpoint was to evaluate the change in items score of comprehensive geriatric assessment (CGA) and health-related quality of life (HRQL). Italian versions of the CGA and HRQL questionnaires were administered at baseline, before the third and fifth cycles, and then every three cycles until treatment discontinuation. Secondary endpoints were efficacy and safety.
RESULTS
Overall, both EQ-5D scores and EQ-5D-3 L visual analogic scale did not significantly change from baseline; the percentage of subjects without problems doing usual activities tended to decrease during treatment (
CONCLUSION
Eribulin treatment preserved quality of life and geriatric parameters included in the CGA, except for instrumental functioning and geriatric depression, in elderly patients with MBC.
IMPLICATIONS FOR PRACTICE
A collaboration between oncologist and geriatric specialists is essential in the management of patients with metastatic breast cancer, who are frequently elderly or frail. The assessment of geriatric parameters in the decision-making process can contribute to direct toward the most appropriate therapeutic plan and preserve the quality of life of patients. Eribulin does not seem to affect quality of life or worsen the overall geriatric status; therefore, it can be considered a suitable option for elderly patients with metastatic breast cancer.
Identifiants
pubmed: 30413667
pii: theoncologist.2017-0676
doi: 10.1634/theoncologist.2017-0676
pmc: PMC6656485
doi:
Substances chimiques
Antineoplastic Agents
0
Furans
0
Ketones
0
Tubulin Modulators
0
eribulin
LR24G6354G
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e232-e240Informations de copyright
© AlphaMed Press 2018.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Future Oncol. 2017 Apr;13(11s):5-10
pubmed: 28481186
Breast. 2014 Feb;23(1):81-7
pubmed: 24314824
J Clin Oncol. 2005 Oct 1;23(28):6865-72
pubmed: 16192578
Mayo Clin Proc. 2009 Jun;84(6):533-45
pubmed: 19483170
Oncotarget. 2017 Feb 2;8(31):50774-50781
pubmed: 28881602
J Clin Oncol. 2010 Jan 20;28(3):380-6
pubmed: 20008637
Ann Acad Med Singapore. 2005 Apr;34(3):250-6
pubmed: 15902346
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):724-30
pubmed: 18693227
Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 4):1-14; quiz 15
pubmed: 24870601
Future Oncol. 2017 May;13(11):971-978
pubmed: 28326833
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Value Health. 2013 Jul-Aug;16(5):814-22
pubmed: 23947975
Breast Cancer (Auckl). 2016 Jun 28;10:77-84
pubmed: 27398025
Eur J Cancer. 2010 Jun;46(9):1502-13
pubmed: 20227872
Lancet Oncol. 2009 Sep;10(9):865-71
pubmed: 19695956
Sci Rep. 2017 Aug 23;7(1):9254
pubmed: 28835702
J Clin Oncol. 2002 Jan 15;20(2):494-502
pubmed: 11786579
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Lancet Oncol. 2012 Apr;13(4):e148-60
pubmed: 22469125
Radiol Technol. 2017 May;88(5):519M-539M
pubmed: 28500107
Expert Opin Pharmacother. 2011 Apr;12(6):945-60
pubmed: 21323593
Breast Cancer. 2010 Jul;17(3):183-9
pubmed: 19756923
Nutrition. 1999 Feb;15(2):116-22
pubmed: 9990575
Ther Adv Med Oncol. 2011 Mar;3(2):57-71
pubmed: 21789156
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
ESMO Open. 2017 Jun 2;2(2):e000176
pubmed: 28761747
Breast Cancer Res Treat. 2015 Dec;154(3):509-20
pubmed: 26567010
JAMA. 1998 Jun 3;279(21):1720-6
pubmed: 9624025
Pharmacoeconomics. 2007;25(5):365-84
pubmed: 17488136
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683